Higher case fatality rate among obstetric patients with COVID-19 in the second year of pandemic in Brazil: do new genetic variants play a role?

Authors

Maíra L S Takemoto, PhD. São Paulo State University (UNESP), Medical School of Botucatu. Address: Av. Prof. Montenegro, s/n - Botucatu - SP, Brazil. Postal code: 18618-687.

Marcos Nakamura-Pereira, PhD. National Institute for Women, Children and Adolescents Health Fernandes Figueira, Oswaldo Cruz Foundation. Address: Av. Rui Barbosa, 716 – Flamengo. Rio de Janeiro - RJ, Brazil. Postal code: 22250-020.

Mariane O Menezes, MSc. São Paulo State University (UNESP), Medical School of Botucatu. Address: Av. Prof. Montenegro, s/n - Botucatu - SP, Brazil. Postal code: 18618-687.

Leila Katz, PhD. Professor Fernando Figueira Institute of Integral Medicine (IMIP). Address: R. dos Coelhos, 300 - Boa Vista, Recife - PE, Brazil. Postal code: 50070-902.

Roxana Knobel, PhD. Federal University of Santa Catarina (UFSC), Department of Gynecology and Obstetrics. Address: R. Eng. Agronômico Andrei Cristian Ferreira, s/n - Trindade, Florianópolis - SC, Brazil. Postal code: 88040-900.

Melania M R Amorim, PhD. Professor Fernando Figueira Institute of Integral Medicine (IMIP). Address: R. dos Coelhos, 300 - Boa Vista, Recife - PE, Brazil. Postal code: 50070-902.

Carla B Andreucci, PhD. Federal University of Sao Carlos (UFSCAR), Department of Medicine. Address: Rodovia Washington Luis, km 235 - São Carlos - SP, Brazil. Postal code: 13565-905.

Corresponding Author

Mariane O Menezes, CPM, MSc, PhD student. Programa de Pós-graduação em Tocoginecologia. São Paulo State University (UNESP), Medical School of Botucatu. Address: Av. Prof. Montenegro, s/n -Botucatu - SP, Brazil. Postal code: 18618-687. Telephone +55 (14) 3880-1134. E-mail: mariane.menezes@unesp.br

Abstract

Background: In Brazil, a 20% increase in maternal mortality rate due to COVID-19 is projected for 2020. On January 4, 2021, the P.1 SARS-CoV-2 genetic variant was firstly identified in the country and recent data has indicated an association with higher hospitalization rates and mortality. The impact of P.1 variant in the obstetric population remains unclear.

Methods: We carried out a preliminary analysis of sociodemographic and clinical characteristics of COVID-19 confirmed maternal deaths (between 10-50 years old) comparing cases reported to the Brazilian official severe acute respiratory syndrome (SARS) surveillance system (SS) in 2020 with those from 2021 (until April 12, 2021). This preliminary analysis employed methods described in previous reports from our group.

Results: 803 maternal deaths out of 8,248 COVID-19 maternal SARS cases with a recorded outcome were reported to the SARS-SS since March 2020. Case fatality rate was significantly higher in 2021 (15.6% vs 7.4%). The first three months of 2021 already account for 46.2% of all deaths occurred in the 13-months analysed period. COVID-19 fatal cases from 2021 had a lower proportion of at least one risk factor or comorbidity as compared to 2020 but had a higher frequency of obesity. There were no significant differences in terms of age, type of residence area (urban, rural, or peri-urban), type of funding of the notification unit (public vs. private), COVID-19 diagnostic criteria, pregnancy status (pregnancy or postpartum), cardiovascular disease or diabetes. The proportion of hospitalization, ICU admission, and **NORES private outpeoptise for cedearth trastras oct being at fifted tily peif ferents** and should not be used to guide clinical practice.

Conclusion: Case fatality rate was increased in the three first months of 2021 when compared to 2020. Once variables related to health care access and demographics are not significantly different and women seem to be healthier in the 2021 sample, such difference may be related to the circulation of more aggressive genetic variants in the country.

The COVID-19 pandemic inflicted an overwhelming burden upon the Brazilian obstetric population^{1,2}. It is estimated that it has already been responsible for a 20% increase in maternal mortality rate in the country in 2020³. Analysis from the Brazilian official severe acute respiratory syndrome (SARS) surveillance system (SS) observed worse outcomes in obstetric patients with older age and comorbidities, in concordance with findings for the general population⁴. Socioeconomic factors that reflect barriers to access healthcare seems to have adversely impacted COVID-19-related maternal mortality in Brazil⁵. Considering maternal death as a sentinel event to assess health in a population, the Brazilian historically overloaded and underfunded healthcare system collapse is likely playing a role in such tragedy.

On January 4, 2021, the P.1 SARS-CoV-2 genetic variant was firstly identified in Brazil. Since the description of the strain, epidemiology of COVID-19 infection in the general Brazilian population seems to have changed. Published reports have shown greater community transmissibility of the P.1 variant, accompanied by increase in mortality rates, particularly in younger people^{6,7}. In February 2021, a study conducted in an area with exponentially increasing hospitalisation rate in the South region identified the P.1 variant in 24 out of 27 SARS-CoV-2 samples.⁶

To examine if the profile of COVID-19 maternal deaths is also modified after the new variant identification, we carried out a preliminary analysis of sociodemographic and clinical characteristics of COVID-19 confirmed maternal deaths comparing cases reported to the SARS-SS in 2020 and 2021 (in both public and private hospitals, until April 12, 2021). This preliminary analysis follows methods described in previous reports from our group^{4,5}.

Findings by year of notification in the SARS-SS are displayed in Table 1. Case fatality rate was significantly higher in 2021 (15.6% vs 7.4%) with 803 maternal deaths out of 8,248 COVID-19 SARS maternal cases with a recorded outcome since March 2020. The first three months of 2021 already account for 46.2% of all deaths occurred in the 13-months analysed period. At the same time, the number of SARS notifications in 2021 regardless of the outcome is only 34.4% of the total number for the entire period (3,474 out of 10,080, data not shown).

There was no significant difference in terms of age, type of residence area, type of funding of the notification unit, COVID-19 diagnostic criteria, distribution of pregnancy status, presence of cardiovascular disease or diabetes. The proportion of hospitalization, ICU admission, and respiratory support before death was also not significantly different.

However, the proportion of white women among cases from 2021 was slightly higher, as well as missing data for ethnicity was reduced. There was a reduction in the Northeast region participation in the overall number of deaths in 2021, with a simultaneous increase in South region participation. Fatal cases for 2021 were also less likely to have at least one risk factor (59% had no risk factor or comorbidity) and more likely to be obese. Median time from symptoms onset to inpatient admission due to SARS was slightly longer in 2021, but time from hospital admission to ICU admission, from admission to death, and length of ICU stay before death did not differ. Noteworthy, median time from hospital admission to ICU time was zero days in both years, implying that patients have been admitted already under severe clinical conditions regardless of year of occurrence.

We believe that health system collapse cannot be ruled out as one of the possible reasons for the increase in the case-fatality rate. We examined hospitalized cases with SARS only and barriers to access proper treatment in earlier stages of the disease may have worsen in 2021. For instance, the beginning of 2021 in Brazil was marked by news of collapsed private hospitals all over the country, which did not happen in 2020⁸. However, our preliminary data seems to indicate that in 2021, healthier Brazilian women are dying despite the relative stability of other risk factors. The increased participation of white women as well as from wealthier geographic regions (markedly the South region) reinforces this hypothesis. Our findings are in line with recent reports from the UK indicating that pregnant women may be more affected in the second pandemic wave^{9,10}.

Considering these findings, it is reasonable to believe that new factors have been introduced in the scenario and the impact of the new coronavirus variants may be one of them. The topic should be further studied warranting the inclusion of the obstetric population in genomic surveillance of SARS-CoV-2 in Brazil. Once effective pandemic containment measures including vaccination and mass testing are still not consistently adopted in the country, we are unable to foresee an end for this calamity.

We declare no competing interests.

References

- Nakamura-Pereira M, Andreucci CB, de Oliveira Menezes M, Knobel R, Takemoto MLS.
 Worldwide maternal deaths due to COVID-19: A brief review. *Int J Gynecol Obstet* 2020; 151: 148–50.
- 2 Takemoto MLS, Menezes MO de O, Andreucci CB, *et al.* The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. *Int J Gynecol Obs* 2020; **151**: 154–6.
- 3 Nakamura-Pereira M, Knobel R, Menezes MO, Andreucci CB, Takemoto MLS. The impact of the COVID-19 pandemic on maternal mortality in Brazil: 523 maternal deaths by acute respiratory distress syndrome potentially associated with SARS-CoV-2. *Int J Gynecol Obstet* 2021; **153**: 360–2.
- 4 Menezes MO, Takemoto MLS, Nakamura-Pereira M, *et al.* Risk factors for adverse outcomes among pregnant and postpartum women with acute respiratory distress syndrome due to COVID-19 in Brazil. *Int J Gynecol Obs* 2020; **151**: 415–23.
- 5 Takemoto MLS, Menezes M de O de O, Andreucci CB, *et al.* Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis. *BJOG* 2020; **127**: 1618–26.
- 6 Martins AF, Zavascki AP, Wink PL, *et al.* Detection of SARS-CoV-2 lineage P.1 in patients from a region with exponentially increasing hospitalisation rate, February 2021, Rio Grande do Sul, Southern Brazil. *Euro Surveill* 2021; **26**: 2100276.
- Faria NR, Mellan TA, Whittaker C, *et al.* Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil. *Science* (80-) 2021; : eabh2644.
- 8 Brazil health service in 'worst crisis in its history' BBC News. https://www.bbc.com/news/world-latin-america-56424611 (accessed April 21, 2021).
- 9 Kadiwar S, Smith JJ, Ledot S, *et al.* Were pregnant women more affected by COVID-19 in the second wave of the pandemic? *Lancet (London, England)* 2021; **397**: 1539–40.
- 10 Intensive Care National Audit & Research Centre. ICNARC report on COVID-19 in critical care: England, Wales and Northern Ireland. 2020.

Table 1. Comparison of fatal cases of COVID-19 during pregnancy or postpartum in Brazil by year of notification to SARS-SS (2020 vs. 2021)

	All cases		2020		2021		p-value*
	N	%	n	%	n	%	_
Case fatality rate	803	9.7	432	7.4	371	15.6	<0.001
Age group							
10-19	28	3.5	21	4.9	7	1.9	0.121
20-34	487	60.6	258	59.7	229	61.7	
35-44	268	33.4	144	33.3	124	33.4	
45+	20	2.5	9	2.1	11	3.0	
Ethnicity/Skin color							
White	234	29.8	108	26.2	126	34.0	0.027
Black	55	7.0	39	9.4	16	4.3	
Yellow	7	0.9	5	1.2	2	0.5	
Brown	412	52.6	222	53.8	190	51.2	
Indigenous	6	0.8	3	0.7	3	0.8	
Missing	70	8.9	36	8.7	34	9.2	
Geographic region							
North	139	17.3	61	14.1	78	21.0	<0.001
Northeast	212	26.4	137	31.7	75	20.2	
Mid-West	75	9.3	37	8.6	38	10.3	
Southeast	300	37.4	172	39.8	128	34.5	
South	77	9.6	25	5.8	52	14.0	
Type of residence area							
Urban	652	81.2	352	81.5	300	80.9	0.207
Rural	64	8.0	31	7.2	33	8.9	
Peri-urban	4	0.5	4	0.9	0	0.0	
Missing	83	10.3	45	10.4	38	10.2	
Funding of SARS notification unit							
Public	658	81.9	352	81.5	306	82.5	0.714
Private	145	18.1	80	18.5	65	17.5	
Diagnostic criteria							
Laboratory	729	90.8	393	91.0	336	90.6	
Clinical-Epidemiological	13	1.6	4	0.9	9	2.4	
Clinical	15	1.9	11	2.5	4	1.1	
Clinical-Imaging	33	4.1	16	3.7	17	4.6	
Missing	13	1.6	8	1.9	5	1.3	
Pregnancy status	-		-		-		

Time from hospital admission to death – median (95% CI) (n=771)	11	(10-12)	11	(10-12)	11	(9.1-12)	0.659
Length of ICU stay – median (95% CI) (n=338)	10	(9-11)	11	(9.3-13.7)	9	(7-10.7)	0.269
Time from hospital admission to ICU admission – median (95% CI) (n=543)	0	(0-0)	0	(0-0)	0	(0-0.5)	0.141
Time from symptom onset to inpatient admission – median (95% CI) (n=771)	5	(5-6)	5	(4-5)	6	(5-6)	<0.001
No	161	20.0	101	23.4	60	16.2	
Yes, non-invasive	161	20.0	81	18.8	80	21.6	0.195
Yes, invasive	481	59.9	250	57.9	231	62.3	
Respiratory support							
ICU admission	555	69.1	296	68.5	259	69.8	0.769
Inpatient admission	777	96.8	421	97.5	356	96.0	0.106
Obesity	109	13.6	51	11.8	58	15.6	0.041
Diabetes	103	12.8	63	14.6	40	10.8	0.363
Cardiovascular disease	109	13.6	63	14.6	46	12.4	0.510
No risk factor or comorbidity	439	54.7	220	50.9	219	59.0	0.021
Pregnant	502	62.5	263	60.9	239	64.4	
Postpartum	301	37.5	169	39.1	132	35.6	0.301

CI, confidence interval; ICU, intensive care unit; SARS, severe acute respiratory syndrome; *Chi-square p-values except for the continuous variables (Two-sample Mann-Whitney test)